ALLO Stock Forecast & Price Target

Allogene Therapeutics is supported by a compelling clinical pipeline, led by the ALPHA3 cema-cel program in LBCL, where interim MRD-negative rates of 58.3% versus 16.7% and a 41.6% delta signal meaningful activity alongside a clean safety profile with no CRS, ICANS, or GvHD. Management’s faster-than-expected site activation, already reaching the 80-site goal in July, and the company’s guidance for enrollment completion by YE2027 with an interim EFS analysis in mid-2027, improve visibility into value-driving catalysts. Its $423.6MM cash position and two assets in the clinic, including additional potential readouts over the next 6-12 months, provide financial runway and multiple shots at clinical success that underpin the positive outlook.

Allogene Therapeutics is a clinical-stage cell therapy company facing substantial fundamental risk because its pipeline remains highly dependent on uncertain trial outcomes, regulatory approval, and manufacturing execution in a highly competitive CAR-T market. Despite $4.6MM in 2Q26 collaboration revenues and $423.6MM in cash, the company still posted an EPS loss of ($0.13), with R&D at $30.7MM and elevated SG&A of $20.8MM underscoring ongoing cash burn and limited operating leverage. The bearish view is further reinforced by the need for additional financing, partner dependence for key gene-editing technology, and the possibility that cema-cel and other assets fail to show sufficient efficacy or safety, which could materially undermine long-term value.